Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.

IF 3.8 2区 医学 Q1 HEMATOLOGY
Qingyuan Xu, Linya Wang, Shaoyan Hu, Ning Liao, Diying Shen, Xin Tian, Guoping Hao, Runming Jin, Jianxin Li, Yongjun Fang, Xiuli Ju, Ansheng Liu, Yuanyuan Zhang, Pengli Huang, Jiaole Yu, Ying Wu, Wei Lin, Peijing Qi, Jia Fan, Ruidong Zhang, Yaguang Peng, Huyong Zheng
{"title":"Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.","authors":"Qingyuan Xu, Linya Wang, Shaoyan Hu, Ning Liao, Diying Shen, Xin Tian, Guoping Hao, Runming Jin, Jianxin Li, Yongjun Fang, Xiuli Ju, Ansheng Liu, Yuanyuan Zhang, Pengli Huang, Jiaole Yu, Ying Wu, Wei Lin, Peijing Qi, Jia Fan, Ruidong Zhang, Yaguang Peng, Huyong Zheng","doi":"10.1111/bjh.70211","DOIUrl":null,"url":null,"abstract":"<p><p>To identify early risk factors for disseminated intravascular coagulation (DIC), particularly severe DIC (grade 4-5), in paediatric acute promyelocytic leukaemia (APL). One hundred and eighty-six paediatric APL patients enrolled in the Chinese Children Leukemia Group (CCLG)-APL 2016 study across 38 hospitals nationwide were grouped based on the occurrence and severity of DIC during induction therapy. DIC occurred in 52.2% of patients during induction therapy, with 7.5% developing grade 4-5 DIC. Significant differences were observed between the DIC and non-DIC groups in the proportion of patients with initial white blood cells (WBC) ≥5 × 10<sup>9</sup>/L, initial platelets (PLT) ≤26 × 10<sup>9</sup>/L and arsenic trioxide (ATO) use (p < 0.05). Multivariate analysis identified initial PLT ≤26 × 10<sup>9</sup>/L (p = 0.002, odds ratio [OR] = 2.679, 95% confidence interval [CI]: 1.438-4.992) as an independent risk factor, while induction therapy using realgar-indigo naturalis formula (RIF) was a protective factor (p = 0.030, OR = 0.465, 95% CI: 0.232-0.929). Further analysis revealed that Fms-like tyrosine kinase 3 (FLT3) mutation (p = 0.023, OR = 11.742, 95% CI: 1.405-98.149), initial PLT ≤26 × 10<sup>9</sup>/L (p = 0.017, OR = 13.784, 95% CI: 1.598-118.905) and initial bone marrow blasts ≥90% (p = 0.030, OR = 5.289, 95% CI: 1.178-23.744) were significant risk factors for grade 4-5 DIC. Initial WBC ≥5 × 10<sup>9</sup>/L and PLT ≤26 × 10<sup>9</sup>/L are associated with an increased risk of DIC, with PLT ≤26 × 10<sup>9</sup>/L as an independent risk factor. Compared with ATO, RIF is a protective factor during induction therapy. Additionally, FLT3 mutation, PLT ≤26 × 10<sup>9</sup>/L and initial bone marrow blasts ≥90% are independent risk factors for grade 4-5 DIC.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.70211","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

To identify early risk factors for disseminated intravascular coagulation (DIC), particularly severe DIC (grade 4-5), in paediatric acute promyelocytic leukaemia (APL). One hundred and eighty-six paediatric APL patients enrolled in the Chinese Children Leukemia Group (CCLG)-APL 2016 study across 38 hospitals nationwide were grouped based on the occurrence and severity of DIC during induction therapy. DIC occurred in 52.2% of patients during induction therapy, with 7.5% developing grade 4-5 DIC. Significant differences were observed between the DIC and non-DIC groups in the proportion of patients with initial white blood cells (WBC) ≥5 × 109/L, initial platelets (PLT) ≤26 × 109/L and arsenic trioxide (ATO) use (p < 0.05). Multivariate analysis identified initial PLT ≤26 × 109/L (p = 0.002, odds ratio [OR] = 2.679, 95% confidence interval [CI]: 1.438-4.992) as an independent risk factor, while induction therapy using realgar-indigo naturalis formula (RIF) was a protective factor (p = 0.030, OR = 0.465, 95% CI: 0.232-0.929). Further analysis revealed that Fms-like tyrosine kinase 3 (FLT3) mutation (p = 0.023, OR = 11.742, 95% CI: 1.405-98.149), initial PLT ≤26 × 109/L (p = 0.017, OR = 13.784, 95% CI: 1.598-118.905) and initial bone marrow blasts ≥90% (p = 0.030, OR = 5.289, 95% CI: 1.178-23.744) were significant risk factors for grade 4-5 DIC. Initial WBC ≥5 × 109/L and PLT ≤26 × 109/L are associated with an increased risk of DIC, with PLT ≤26 × 109/L as an independent risk factor. Compared with ATO, RIF is a protective factor during induction therapy. Additionally, FLT3 mutation, PLT ≤26 × 109/L and initial bone marrow blasts ≥90% are independent risk factors for grade 4-5 DIC.

儿科APL DIC的危险因素:来自CCLG-APL 2016研究的见解
确定小儿急性早幼粒细胞白血病(APL)中弥散性血管内凝血(DIC)的早期危险因素,特别是严重DIC(4-5级)。根据诱导治疗期间DIC的发生和严重程度,在全国38家医院的中国儿童白血病组(CCLG)-APL 2016研究中招募了186名儿科APL患者。52.2%的患者在诱导治疗期间发生DIC,其中7.5%发展为4-5级DIC。初始白细胞(WBC)≥5 × 109/L、初始血小板(PLT)≤26 × 109/L和三氧化二砷(ATO)作为独立危险因素的患者比例在DIC组和非DIC组之间存在显著差异(p = 0.002,优势比[OR] = 2.679, 95%可信区间[CI]: 1.438 ~ 4.992),而使用雄黄-靛蓝天然配方(RIF)诱导治疗是一个保护因素(p = 0.030, OR = 0.465, 95% CI: 0.232 ~ 0.929)。进一步分析发现fms样酪氨酸激酶3 (FLT3)突变(p = 0.023, OR = 11.742, 95% CI: 1.405 ~ 98.149)、初始PLT≤26 × 109/L (p = 0.017, OR = 13.784, 95% CI: 1.598 ~ 118.905)、初始骨髓母细胞≥90% (p = 0.030, OR = 5.289, 95% CI: 1.178 ~ 23.744)是4 ~ 5级DIC的显著危险因素。初始WBC≥5 × 109/L、PLT≤26 × 109/L与DIC风险增加相关,其中PLT≤26 × 109/L为独立危险因素。与ATO相比,RIF是诱导治疗过程中的保护因子。FLT3突变、PLT≤26 × 109/L、初始骨髓细胞≥90%是4-5级DIC的独立危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.60
自引率
4.60%
发文量
565
审稿时长
1 months
期刊介绍: The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信